{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:08:58Z","timestamp":1793686138848,"version":"4.5.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Clinical Research Infrastructure"},{"DOI":"10.13039\/501100004836","name":"Danish Council for Independent Research","doi-asserted-by":"crossref","award":["DFF \u2013 6110-00608"],"award-info":[{"award-number":["DFF \u2013 6110-00608"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>MTX is the most commonly recommended DMARD for first-line treatment of RA, however, it has been hypothesized to cause lung disease as an adverse effect. We investigated the risk of interstitial lung disease (ILD) and acute and chronic respiratory failure in persons with RA treated with MTX and other medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>From the Danish National Patient Register (NPR) and the DANBIO register for rheumatic diseases, we retrieved data on 30\u00a0512 persons with RA registered in 1997\u20132015. Information on ILD and respiratory failure was obtained from the NPR. Information on age and sex for all Danish citizens was obtained from the Danish Civil Registration System. MTX and other medication purchases were retrieved from the Danish Prescription Registry. Associations between MTX and lung disease outcomes were analysed in Cox regression models with adjustment for age, calendar time, sex and other medications. Standardized incidence ratios (SIRs) of lung disease were calculated to compare the RA population with the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There was no increased risk of lung disease with MTX treatment [one or more purchases compared with no purchases; HR 1.00 (95% CI 0.78, 1.27) for ILD and 0.54 (95% CI 0.43, 0.67) for respiratory failure] at the 5\u2009year follow-up. The SIR was three to four times higher for ILD in MTX-treated persons with RA, but similar to the whole RA population compared with the background population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Persons with RA had an increased risk of ILD compared with the general population, but there was no further increased risk associated with MTX treatment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa327","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T19:12:50Z","timestamp":1590433970000},"page":"346-352","source":"Crossref","is-referenced-by-count":73,"title":["Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: a nationwide population-based study"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5253-8465","authenticated-orcid":false,"given":"Else Helene","family":"Ibfelt","sequence":"first","affiliation":[{"name":"Steno Diabetes Center Copenhagen, Capital Healthcare Region, Gentofte, Denmark"},{"name":"Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"},{"name":"Danish Clinical Registries, A National Quality Improvement Programme, Central Denmark Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke Kart","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine Iskov","family":"Kopp","sequence":"additional","affiliation":[{"name":"Department of Neurology, Danish Multiple Sclerosis Registry, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-2574","authenticated-orcid":false,"given":"Ren\u00e9 Lindholm","family":"Cordtz","sequence":"additional","affiliation":[{"name":"Centre for Rheumatology and Spine Diseases, Denmark, Rigshospitalet \u2013 Gentofte, Denmark"},{"name":"Department of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Svarre","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Herlev and Gentofte University Hospital, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Seersholm","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Herlev and Gentofte University Hospital, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saher Burhan","family":"Shaker","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Herlev and Gentofte University Hospital, Gentofte, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Rheumatology, Aalborg University and Aalborg University Hospital, Aalborg, Denmark"},{"name":"DANBIO registry, Rigshospitalet - Glostrup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"key":"2021010517014918200_keaa327-B1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1874312900701010018","article-title":"Prevalence of rheumatoid arthritis in the southern part of Denmark","volume":"1","author":"Pedersen","year":"2007","journal-title":"Open Rheumatol J"},{"key":"2021010517014918200_keaa327-B2","first-page":"31","volume-title":"Epidemiology of the rheumatic diseases","author":"Silman","year":"2001"},{"key":"2021010517014918200_keaa327-B3","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"2021010517014918200_keaa327-B4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ccm.2010.04.003","article-title":"Pulmonary manifestations of rheumatoid arthritis","volume":"31","author":"Antin-Ozerkis","year":"2010","journal-title":"Clin Chest Med"},{"key":"2021010517014918200_keaa327-B5","doi-asserted-by":"crossref","first-page":"238","DOI":"10.3389\/fmed.2019.00238","article-title":"Methotrexate-associated pneumonitis and rheumatoid arthritis-interstitial lung disease: current concepts for the diagnosis and treatment","volume":"6","author":"Fragoulis","year":"2019","journal-title":"Front Med"},{"key":"2021010517014918200_keaa327-B6","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2021010517014918200_keaa327-B7","first-page":"21","article-title":"Rheumatoid arthritis-associated interstitial lung disease","volume":"4","author":"Solomon","year":"2012","journal-title":"Open Access Rheumatol Res Rev"},{"key":"2021010517014918200_keaa327-B8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021010517014918200_keaa327-B9","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"2021010517014918200_keaa327-B10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021010517014918200_keaa327-B11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/CLEP.S99490","article-title":"The Danish nationwide clinical register for patients with rheumatoid arthritis: DANBIO","volume":"8","author":"Ibfelt","year":"2016","journal-title":"Clin Epidemiol"},{"key":"2021010517014918200_keaa327-B12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021010517014918200_keaa327-B13","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021010517014918200_keaa327-B14","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1183\/09031936.02.00267402","article-title":"Sulphasalazine and lung toxicity","volume":"19","author":"Parry","year":"2002","journal-title":"Eur Respir J"},{"key":"2021010517014918200_keaa327-B15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/03009740601153774","article-title":"Rheumatoid arthritis treatment and the risk of severe interstitial lung disease","volume":"36","author":"Wolfe","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"2021010517014918200_keaa327-B16","doi-asserted-by":"crossref","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open"},{"key":"2021010517014918200_keaa327-B17","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1002\/art.38733","article-title":"Methotrexate and lung disease in rheumatoid arthritis: comment on the article by Conway et al","volume":"66","author":"Rojas-Serrano","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2021010517014918200_keaa327-B18","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021010517014918200_keaa327-B19","doi-asserted-by":"crossref","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"BMJ"},{"key":"2021010517014918200_keaa327-B20","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2021010517014918200_keaa327-B21","doi-asserted-by":"crossref","first-page":"627","DOI":"10.2147\/CLEP.S141438","article-title":"Validity and completeness of rheumatoid arthritis diagnoses in the nationwide DANBIO clinical register and the Danish National Patient Registry","volume":"9","author":"Ibfelt","year":"2017","journal-title":"Clin Epidemiol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/346\/35433369\/keaa327.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/1\/346\/35433369\/keaa327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T08:29:12Z","timestamp":1610267352000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/1\/346\/5891279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,11]]},"published-print":{"date-parts":[[2021,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa327","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1]]},"published":{"date-parts":[[2020,8,11]]}}}